Pasar al contenido principal

CONTROL METABOLICO Y TRANSCRIPCIONAL DURANTE LA RESISTENCIA A TRATAMIENTO EN GLIOBLASTOMA MULTIFORME

PID2021-124251OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Robust Method for the Unsupervised Scoring of Immunohistochemical Staining

  • Durán-Díaz, Iván
  • Sarmiento, Auxiliadora
  • Fondón, Irene
  • Bodineau, Clément
  • Tomé, Mercedes
  • Durán, Raúl V.
Immunohistochemistry is a powerful technique that is widely used in biomedical research and clinics; it allows one to determine the expression levels of some proteins of interest in tissue samples using color intensity due to the expression of biomarkers with specific antibodies. As such, immunohistochemical images are complex and their features are difficult to quantify. Recently, we proposed a novel method, including a first separation stage based on non-negative matrix factorization (NMF), that achieved good results. However, this method was highly dependent on the parameters that control sparseness and non-negativity, as well as on algorithm initialization. Furthermore, the previously proposed method required a reference image as a starting point for the NMF algorithm. In the present work, we propose a new, simpler and more robust method for the automated, unsupervised scoring of immunohistochemical images based on bright field. Our work is focused on images from tumor tissues marked with blue (nuclei) and brown (protein of interest) stains. The new proposed method represents a simpler approach that, on the one hand, avoids the use of NMF in the separation stage and, on the other hand, circumvents the need for a control image. This new approach determines the subspace spanned by the two colors of interest using principal component analysis (PCA) with dimension reduction. This subspace is a two-dimensional space, allowing for color vector determination by considering the point density peaks. A new scoring stage is also developed in our method that, again, avoids reference images, making the procedure more robust and less dependent on parameters. Semi-quantitative image scoring experiments using five categories exhibit promising and consistent results when compared to manual scoring carried out by experts., This research was funded by grant PID2021-123090NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; by grant PID2021-124251OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; and by FEDER/Junta de Andalucía-Consejería de Economía y Conocimiento, grant number US-1264994., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations

  • Olmedo-Moreno, Laura
  • Panadero-Morón, Concepción
  • Sierra-Párraga, Jesús María
  • Bueno-Fernández, Rubén
  • Norton, Emily S.
  • Aguilera García, Yolanda
  • Mellado-Damas, Nuria
  • García-Tárraga, Patricia
  • Morales-Gallel, Raquel
  • Antequera-Martínez, María
  • Durán, Raúl V.
  • Ferrer-Lozano, Jaime
  • Escames, Germaine
  • García-Verdugo, José Manuel
  • Martín-Montalvo, Alejandro
  • Guerrero-Cázares, Hugo
  • Capilla-González, Vivian
Rationale: Glioblastoma (GBM) is the most fatal form of brain cancer and its treatment represents a persistent challenge. Mesenchymal stromal cells (MSCs) have been explored as therapeutic tools in cancer management owing to their tumor-homing abilities. However, their clinical application is limited due to the controversial role of MSCs in carcinogenesis. This study investigates how MSCs influence tumor behavior and explores the synergistic anticancer effects in combination with melatonin (Mel). Methods: Orthotopic and subcutaneous GBM xenograft mouse models were used to assess the antitumor effect of Mel pre-treated MSCs (MSCMel). Histological, immunohistochemical, and ultrastructural analyses were conducted to identify phenotypic changes in tumors. Through a set of in vitro assays, including direct and indirect co-cultures, dynamic single-cell tracking and tumorsphere assay, we explored the impact of MSCMel on primary and non-primary GBM cells. Transcriptomic profiling was used to identify genes and pathways modulated by this synergistic therapy. Results: MSCMel delayed tumor growth in mice and increased collagen deposition. Additionally, MSCMel showed enhanced capacity to prevent GBM cell migration compared to untreated MSCs. Molecular analysis identified genes and proteins related to cell migration, cytoskeletal dynamics and extracellular matrix remodeling in GBM cells exposed to MSCMel, including reduced vimentin expression. Finally, a genetic signature associated with the clinical outcomes of GBM patients was identified. Conclusions: Our study demonstrates that melatonin enhances the anticancer properties of MSCs, providing new insights into their interaction with GBM cells and tumor environment. These findings offer valuable guidance for advancing MSC-based therapies in clinical practice., This research was funded by the Institute of Health Carlos III, co-funded by Fondos FEDER (PI23/00315, PI20/00341 and CP19/00046 to VC-G) and the Asociación Española Contra el Cancer (IDEAS20051CAPI to VC-G). LO-M is supported by the Spanish Ministry of Science, Innovation and Universities (FPU19/04703). JMS-P was supported by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades of Junta de Andalucia, co-funded by Fondos FEDER (POSTDOC/21/00424) and the Institute of Health Carlos III, co-funded by Eropean Union (CD23/00104). CP-M is supported by the Asociación Pablo Ugarte. RM-G is supported by the Asociación Española Contra el Cancer (PRDVA222457MORA). RV-D. was supported by Grant PID2021- 124251OB-I00 and Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/UE. AM-M is supported by the Ministerio de Ciencia e Innovación (PID2021-123965OB-100). HG-C is supported by the National Institute of Neurological Disorders and Stroke and internal Mayo Clinic funds. JMG-V was supported by the Valencian Council for Education, Culture, University and Employment (CIPROM/2023/053)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer

  • Morillo-Huesca, Macarena
  • López-Cepero, Ignacio G.
  • Conesa-Bakkali, Ryan
  • Tomé, Mercedes
  • Watts, Colin
  • Huertas, Pablo
  • Moreno-Bueno, Gema
  • Durán, Raúl V.
  • Martínez-Fábregas, Jonathan
Tumor resistance represents a major challenge in the current oncology landscape. Asparagine endopeptidase (AEP) overexpression correlates with worse prognosis and reduced overall survival in most human solid tumors. However, the underlying mechanisms of the connection between AEP and reduced overall survival in cancer patients remain unclear., Research and publication of this work was funded by the EMERGIA 2021 program (EMERGIA21_00124) from the Consejería de Universidad, Investigación e Innovación, Junta de Andalucía, Spain to J.M-F. J.M-F. was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie programme (101025429), the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, RYC2021-032389), the Consejería de Universidad, Investigación e Innovación under the EMERGIA program (EMC21_00124) Junta de Andalucia, and the VII PPIT of the University of Seville (2023/00000479). RVD and G.M-B were supported by MICINN-AEI and European Regional Development Fund (project PID2021-124251OB-I00 and PID2022-136854OB-I00, respectively). G.M-B was also funded by The Instituto de Salud Carlos III IISCIII, CIBERONC (CB16/12/00295) and ERA PerMed ERA-NET co-funded by the NextGeneration-EU (ISCIII and Fundacion cientifica AECC, AC21_2/00020). PH was supported by R + D + I grant (PID2019-104195G) from the Spanish Ministry of Science and Innovation-Agencia Estatal de Investigación/10.13039/501100011033. CW was supported by a Welcome Trust Programme Grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance

  • Zarzuela, Laura
  • Durán, Raúl V
  • Tomé, Mercedes
Glioblastoma is the most common form of primary malignant brain tumor in adults and one of the most lethal human cancers, with high recurrence and therapy resistance. Glioblastoma cells display extensive genetic and cellular heterogeneity, which precludes a unique and common therapeutic approach. The standard of care in glioblastoma patients includes surgery followed by radiotherapy plus concomitant temozolomide. As in many other cancers, cell signaling is deeply affected due to mutations or alterations in the so-called molecular drivers. Moreover, glioblastoma cells undergo metabolic adaptations to meet the new demands in terms of energy and building blocks, with an increasing amount of evidence connecting metabolic transformation and cell signaling deregulation in this type of aggressive brain tumor. In this review, we summarize some of the most common alterations both in cell signaling and metabolism in glioblastoma, presenting an integrative discussion about how they contribute to therapy resistance. Furthermore, this review aims at providing a comprehensive overview of the state-of-the-art of therapeutic approaches and clinical trials exploiting signaling and metabolism in glioblastoma., RVD and MT were supported by Spanish Ministry of Science and Innovation, Spanish Research Agency, and European Regional Development Fund (project PID2021-124251OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE). LZ was supported by FPU fellowship (FPU19/04914) from the Spanish Ministry of Universities. Figures created with BioRender.com., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

  • Zarzuela, Laura
  • López-Cepero, Ignacio G.
  • Rattigan, Kevin M.
  • Reina-Bando, Ana
  • Martín-Montalvo, Jorge
  • Sierra-Párraga, Jesús M.
  • Sánchez-Escabias, Elena
  • Morillo-Huesca, Macarena
  • Oltra, Sara S.
  • Ceballos-Chávez, María
  • Capilla-González, Vivian
  • Moreno-Bueno, Gema
  • Murdoch, Piedad del Socorro
  • Reyes, José C.
  • Helgason, G. Vignir
  • Tomé, Mercedes
  • Durán, Raúl V.
Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1 pathway as a major controller of the signaling and metabolic rewiring associated to temozolomide (TMZ) resistance. Hence, in FGFR1-positive, p53 WT GBM cells, FGFR1 controls a p53-mediated cell cycle arrest to allow DNA repair in response to TMZ. FGFR1 also regulates a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Indeed, FGFR1 inhibition completely abolishes this signaling and metabolic reprograming, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 with poor prognosis in GBM patients, and validated the dual treatment with TMZ and FGFR1 inhibitors as an efficient strategy to induce tumor cell death in FGFR1-positive, p53 WT pre-clinical animal GBM models. These data position FGFR1 as a promising candidate for future clinical evaluation to limit therapy resistance to TMZ in FGFR1-positive GBM patients., Grants PID2021-124251OB-I00 and PID2024-156338OB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (RVD, MTM). Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU (RVD, MTM) Grant PID2023-149538NB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (JCR). Predoctoral FPU contract (FPU19/04914) from the Spanish Ministry of Universities (LZM). Predoctoral contract (PREDOC_00345) funded by PAIDI, Junta de Andalucia (IGLC). Predoctoral FPI contract (PRE2022-101357) funded by Spanish MICIU/AEI/10.13039/501100011033 and FSE+ (ARB). Predoctoral contract (PRDSE258639MART) from Asociación Española Contra el Cáncer (JMM). Grant PI23/00315 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (VCG). Grant CD23/00104 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (JMSP). Grant RyC2023-043933-I funded by Spanish Ministerio de Ciencia, Innovacion y Universidades (VCG). Grant A29754 funded by Cancer Research UK, UK (GVH). Grant CB16/12/00295 funded by Spanish CIBERONC (GMB). Grant PID2022-136854OB-I00 funded by MICIU/AEI/10.13039/501100011033 (GMB)., Peer reviewed